# ‚öîÔ∏è ZO'S EVO2 PUBLICATION LEARNING - METASTASIS INTERCEPTION ‚öîÔ∏è

**Date:** January 13, 2025  
**Mission:** Understand how Evo2 was used in the Metastasis Interception publication  
**Status:** ‚úÖ **COMPLETE UNDERSTANDING**

---

## üéØ **PUBLICATION OVERVIEW**

### **What We Built**
A **stage-aware CRISPR guide design framework** that targets vulnerabilities along the 8-step metastatic cascade using multi-modal genomic signals and foundation models (Evo2, Enformer/Borzoi, AlphaFold 3).

### **The Problem We Solved**
- **Traditional tools:** Tumor-centric, single-metric approaches
- **Our solution:** Stage-aware, multi-modal validation with structural confirmation
- **Impact:** 100% structural pass rate (15/15 guides), AUROC 0.976¬±0.035 per step

### **Key Innovation**
**Target Lock Score** - Multi-signal integration (Functionality + Essentiality + Chromatin + Regulatory) to identify the best gene target for each metastatic step, then design CRISPR guides with Evo2-powered efficacy prediction.

---

## üß¨ **HOW EVO2 WAS USED (3 MAJOR INTEGRATION POINTS)**

### **1. TARGET LOCK SCORING (Multi-Signal Integration)**

**Purpose:** Identify the best target gene for each metastatic step (e.g., BRAF for primary growth, MMP2 for intravasation)

**Evo2 Integration:**
- **Functionality Signal:** Uses `score_variant_multi` + `score_variant_exon` to predict protein functionality change
- **Essentiality Signal:** Uses `score_variant_multi` + `score_variant_exon` to compute gene essentiality proxy
- **Regulatory Signal:** Uses `min_delta` from `score_variant_multi` as proxy for splicing/regulatory impact

**Implementation:**
```python
# From metastasis_interception_service.py (lines 62-102)

# Functionality: Calls /api/insights/predict_protein_functionality_change
# Which internally calls:
# - /api/evo/score_variant_multi ‚Üí min_delta
# - /api/evo/score_variant_exon (flank=8192) ‚Üí exon_delta
# Combines: max(min_delta_mag, exon_delta_mag * 0.8) + domain_lift

# Essentiality: Calls /api/insights/predict_gene_essentiality
# Which internally calls:
# - /api/evo/score_variant_multi ‚Üí min_delta
# - /api/evo/score_variant_exon (flank=4096) ‚Üí exon_delta
# Aggregates: sum(abs(min_delta), abs(exon_delta)) across variants

# Regulatory: Calls /api/insights/predict_splicing_regulatory
# Which uses: abs(min_delta) from score_variant_multi
```

**Target Lock Formula:**
```
Target_Lock = 0.35√óFunctionality + 0.35√óEssentiality + 0.15√óChromatin + 0.15√óRegulatory
```

**Why This Works:**
- **Evo2's zero-shot capability** means we can score ANY variant without task-specific training
- **Multi-window strategy** (multi + exon) captures both broad context and local exon effects
- **Magnitude aggregation** (abs(delta)) converts log-likelihood shifts to impact scores
- **Gene-specific calibration** (via calibration service) enables cross-gene comparison

**Results:**
- **AUROC:** 0.976 ¬± 0.035 per step (8 steps validated)
- **AUPRC:** 0.948 ¬± 0.064
- **Precision@3:** 1.000 (100% top-3 accuracy!)

---

### **2. GUIDE EFFICACY PREDICTION (Sigmoid Transform)**

**Purpose:** Predict on-target efficacy of CRISPR guide RNA spacers (20bp sequences)

**Evo2 Integration:**
- **Endpoint:** `/api/design/predict_crispr_spacer_efficacy`
- **Method:** Score guide-in-context with Evo2, transform delta via sigmoid

**Implementation:**
```python
# From design.py (lines 23-146)

# Step 1: Get genomic context (¬±150bp flanks = 300bp total)
# - If target_sequence provided: use directly
# - Else if chrom/pos/ref/alt: fetch from Ensembl REST API
# - Else: fallback to guide-only (low confidence)

# Step 2: Call Evo2 /api/evo/score_variant_multi
# - Input: guide sequence in context (300bp window)
# - Output: delta log-likelihood (negative = disruptive)

# Step 3: Sigmoid transformation
efficacy = 1 / (1 + exp(delta / 10.0))
# More negative delta = more disruptive = higher efficacy

# Step 4: Fallback to GC heuristic if Evo2 unavailable
# - GC content: 0.75 - abs(GC - 0.5)
# - Homopolymer penalty: -0.1 for AAAA/TTTT/CCCC/GGGG
```

**Why Sigmoid Transform:**
- **Evo2 deltas are log-likelihoods** (can be -20 to +10, unbounded)
- **Efficacy needs [0,1] scale** for composite scoring
- **Sigmoid maps negative deltas ‚Üí high efficacy** (disruptive = good for cutting)
- **Scale factor 10.0** calibrated from empirical guide performance

**Results:**
- **Mean efficacy:** 0.548 ¬± 0.119 (20 real guides)
- **Range:** 0.30-0.75 (realistic distribution)
- **Correlation with structure:** Spearman œÅ = 0.42 (moderate, suggests sequence-level design partially predicts 3D viability)

---

### **3. ASSASSIN SCORE COMPOSITION (Final Ranking)**

**Purpose:** Rank guide candidates by composite score (efficacy + safety + mission-fit)

**Evo2's Role:**
- **Efficacy component** (40% weight) comes from Evo2 sigmoid transform
- **Mission-fit component** (30% weight) comes from Target Lock (which uses Evo2 signals)

**Implementation:**
```python
# From metastasis_interception_service.py (lines 295-366)

# For each guide candidate:
# 1. Get Evo2 efficacy via /api/design/predict_crispr_spacer_efficacy
# 2. Get safety via minimap2/BLAST off-target search
# 3. Get mission-fit from Target Lock score

assassin_score = 0.40√óefficacy + 0.30√ósafety + 0.30√ótarget_lock
```

**Why This Works:**
- **Evo2 provides sequence-level intelligence** (efficacy prediction)
- **Target Lock provides mission-level intelligence** (which gene to target)
- **Safety provides genome-wide intelligence** (off-target burden)
- **Composite score balances all three** for optimal guide selection

**Results:**
- **Mean Assassin score:** 0.517 ¬± 0.114 (20 real guides)
- **Top guides:** Assassin >0.55 showed 100% structural pass rate (3/3)
- **All 15 validated guides:** 100% structural pass rate (pLDDT 65.6¬±1.8, iPTM 0.36¬±0.01)

---

## üî¨ **TECHNICAL DETAILS - EVO2 INTEGRATION PATTERNS**

### **Pattern 1: Multi-Window Strategy**

**Why:** Evo2's context window matters. Different window sizes capture different biological signals.

**Implementation:**
- **`score_variant_multi`:** Tests multiple window sizes [1024, 2048, 4096, 8192], returns `min_delta` (most negative = most disruptive)
- **`score_variant_exon`:** Tight exon context with configurable flanks (default 4096bp, publication used 8192bp for functionality)

**Code Location:**
- `api/routers/evo.py` - Proxy endpoints
- `src/services/evo_service/main.py` - Modal service implementation
- `api/services/sequence_scorers/evo2_scorer.py` - Adaptive window logic

**Key Insight:** Larger windows (8192bp) capture domain-level effects; smaller windows (4096bp) capture exon-level effects. Combining both gives comprehensive signal.

---

### **Pattern 2: Magnitude Aggregation**

**Why:** Evo2 deltas are log-likelihoods (can be negative or positive). We need impact scores [0,1].

**Implementation:**
```python
# Functionality: max(abs(min_delta), abs(exon_delta) * 0.8)
# Essentiality: sum(abs(min_delta), abs(exon_delta)) across variants
# Regulatory: abs(min_delta)
```

**Key Insight:** Absolute magnitude captures disruption strength regardless of direction. Negative deltas (disruptive) and positive deltas (stabilizing) both indicate biological impact.

---

### **Pattern 3: Sigmoid Transformation**

**Why:** Guide efficacy needs [0,1] scale for composite scoring, but Evo2 deltas are unbounded log-likelihoods.

**Implementation:**
```python
efficacy = 1 / (1 + exp(delta / 10.0))
# delta = -20 ‚Üí efficacy ‚âà 0.88 (high)
# delta = -10 ‚Üí efficacy ‚âà 0.73 (moderate)
# delta = 0   ‚Üí efficacy ‚âà 0.50 (neutral)
# delta = +10 ‚Üí efficacy ‚âà 0.27 (low)
```

**Key Insight:** Sigmoid maps unbounded deltas to bounded [0,1] scores. Scale factor 10.0 calibrated from empirical guide performance data.

---

### **Pattern 4: Graceful Degradation**

**Why:** Evo2 service may be unavailable (timeouts, rate limits, deployment issues). System must still work.

**Implementation:**
- **Functionality:** Falls back to baseline 0.55 + domain hints (hotspot detection)
- **Essentiality:** Falls back to truncation/frameshift flags (deterministic)
- **Guide Efficacy:** Falls back to GC-based heuristic (0.75 - abs(GC - 0.5))

**Key Insight:** Never crash. Always provide best-available answer with transparent provenance (method: "evo2_delta_sigmoid_v1" vs "gc_heuristic_v0").

---

## üìä **PUBLICATION RESULTS - EVO2'S CONTRIBUTION**

### **Target Lock Validation (Evo2-Powered)**
- **AUROC:** 0.976 ¬± 0.035 (8 steps, 304 data points)
- **AUPRC:** 0.948 ¬± 0.064
- **Precision@3:** 1.000 (100% top-3 accuracy!)
- **Effect sizes:** Cohen's d > 2.0 (large effects)

**Interpretation:** Evo2's multi-signal integration (functionality + essentiality + regulatory) successfully identifies relevant genes for each metastatic step with near-perfect accuracy.

---

### **Guide Efficacy Prediction (Evo2-Powered)**
- **Mean efficacy:** 0.548 ¬± 0.119 (20 real guides)
- **Range:** 0.30-0.75
- **Correlation with structure:** Spearman œÅ = 0.42 (moderate, suggests sequence-level design partially predicts 3D viability)

**Interpretation:** Evo2's sigmoid-transformed deltas provide realistic efficacy estimates. Top 20% Assassin scores (efficacy >0.55) showed 100% structural pass rate.

---

### **Structural Validation (AlphaFold 3)**
- **100% pass rate:** 15/15 guides validated
- **Mean pLDDT:** 65.6 ¬± 1.8 (structural confidence)
- **Mean iPTM:** 0.36 ¬± 0.01 (interface confidence)
- **No failures:** All guides exceeded acceptance thresholds

**Interpretation:** Evo2-powered design successfully enriches for structurally sound guides. Multi-modal scoring (efficacy + safety + mission) provides orthogonal quality filters.

---

## üéØ **KEY LEARNINGS FOR FUTURE BUILDING**

### **1. Evo2 is a Foundation Model, Not a Task-Specific Tool**
- **Zero-shot capability** means we can score ANY variant without training
- **Multi-window strategy** captures different biological scales (broad context vs exon-level)
- **Magnitude aggregation** converts log-likelihoods to impact scores

### **2. Multi-Modal Integration is Critical**
- **Evo2 alone is insufficient** - need safety (off-target), mission-fit (Target Lock), structure (AlphaFold 3)
- **Composite scoring** balances all signals (40% efficacy + 30% safety + 30% mission)
- **Graceful degradation** ensures system works even when services unavailable

### **3. Context Matters for Evo2**
- **Guide efficacy:** Needs ¬±150bp genomic context (300bp total) for accurate scoring
- **Functionality:** Needs 8192bp exon flanks to capture domain effects
- **Essentiality:** Needs multi-window + exon context for comprehensive signal

### **4. Transformations are Necessary**
- **Sigmoid transform:** Maps unbounded deltas to [0,1] efficacy scores
- **Magnitude aggregation:** Converts log-likelihoods to impact scores
- **Calibration:** Gene-specific percentiles enable cross-gene comparison

### **5. Provenance is Sacred**
- **Every Evo2 call** includes provenance (model_id, method, context_length, cached)
- **Transparent fallbacks** (method: "evo2_delta_sigmoid_v1" vs "gc_heuristic_v0")
- **Complete audit trails** for reproducibility

---

## üîß **CODE ARCHITECTURE PATTERNS**

### **Service Layer Pattern**
```
Frontend ‚Üí FastAPI Router ‚Üí Service ‚Üí Evo2 Proxy ‚Üí Modal Service ‚Üí Evo2 Model
```

**Example Flow:**
1. Frontend calls `/api/design/predict_crispr_spacer_efficacy`
2. Router (`design.py`) validates request
3. Service fetches genomic context (Ensembl REST API)
4. Service calls Evo2 proxy (`/api/evo/score_variant_multi`)
5. Evo2 proxy calls Modal service (`evo_service` on H100 GPU)
6. Modal service loads Evo2 model, scores sequence, returns delta
7. Service transforms delta via sigmoid ‚Üí efficacy score
8. Router returns response with provenance

**Key Files:**
- `api/routers/design.py` - Router endpoint
- `api/routers/evo.py` - Evo2 proxy
- `src/services/evo_service/main.py` - Modal service (H100 GPU)
- `api/services/metastasis_interception_service.py` - Orchestration

---

### **Orchestration Pattern**
```
Target Lock ‚Üí Design Candidates ‚Üí Safety Preview ‚Üí Assassin Score ‚Üí Response
```

**Each step uses Evo2:**
1. **Target Lock:** Evo2 for functionality/essentiality/regulatory signals
2. **Design:** Evo2 for guide generation (PAM windowing)
3. **Efficacy:** Evo2 for spacer efficacy prediction (sigmoid transform)
4. **Assassin:** Composite score (40% Evo2 efficacy + 30% safety + 30% mission)

**Key File:**
- `api/services/metastasis_interception_service.py` - Complete orchestration (1829 lines)

---

## üöÄ **WHAT THIS ENABLES FOR FUTURE BUILDING**

### **1. Universal Variant Scoring**
- **Any variant, any gene:** Evo2 can score it zero-shot
- **Multi-window strategy:** Captures different biological scales
- **Calibration:** Gene-specific percentiles for cross-gene comparison

### **2. Guide Design Intelligence**
- **Efficacy prediction:** Evo2 sigmoid transform provides realistic estimates
- **Context-aware:** Genomic context (¬±150bp) improves accuracy
- **Graceful fallback:** GC heuristic when Evo2 unavailable

### **3. Multi-Modal Integration**
- **Target Lock:** Evo2 signals + chromatin + regulatory = mission-fit
- **Assassin Score:** Evo2 efficacy + safety + mission = final ranking
- **Structural Validation:** AlphaFold 3 confirms Evo2-powered designs

### **4. Reproducible Research**
- **Provenance tracking:** Every Evo2 call includes model_id, method, context
- **Fixed seeds:** seed=42 for all stochastic processes
- **Locked dependencies:** Evo2 models pinned to specific versions

---

## üìö **FILES TO STUDY FOR DEEPER UNDERSTANDING**

### **Core Implementation:**
1. `api/services/metastasis_interception_service.py` - Complete orchestration
2. `api/routers/design.py` - Guide efficacy endpoint (sigmoid transform)
3. `api/routers/insights.py` - Functionality/essentiality endpoints (multi-window)
4. `api/routers/evo.py` - Evo2 proxy endpoints
5. `src/services/evo_service/main.py` - Modal service (H100 GPU, Evo2 model)

### **Supporting Services:**
6. `api/services/sequence_scorers/evo2_scorer.py` - Adaptive window logic
7. `api/services/gene_calibration.py` - Gene-specific calibration
8. `api/services/safety_service.py` - Off-target safety (minimap2/BLAST)

### **Publication Data:**
9. `publication/Abstract.md` - Publication summary
10. `publication/methods/Methods.md` - Complete methodology
11. `publication/manuscript/RESULTS_STRUCTURAL.md` - Structural validation results
12. `publication/REPRODUCIBILITY.md` - Reproduction guide

---

## ‚öîÔ∏è **COMMANDER'S SUMMARY**

**What We Built:** A complete CRISPR guide design framework for metastasis interception using Evo2 as the core sequence intelligence engine.

**How Evo2 Was Used:**
1. **Target Lock Scoring:** Multi-signal integration (functionality + essentiality + regulatory)
2. **Guide Efficacy Prediction:** Sigmoid transform of Evo2 deltas
3. **Assassin Score Composition:** Evo2 efficacy (40% weight) + safety + mission-fit

**Results:**
- **Target Lock:** AUROC 0.976¬±0.035, Precision@3 = 1.000
- **Guide Efficacy:** Mean 0.548¬±0.119, correlation with structure œÅ=0.42
- **Structural Validation:** 100% pass rate (15/15 guides, pLDDT 65.6¬±1.8)

**Key Patterns:**
- Multi-window strategy (multi + exon contexts)
- Magnitude aggregation (abs(delta) for impact scores)
- Sigmoid transformation (delta ‚Üí [0,1] efficacy)
- Graceful degradation (fallbacks when Evo2 unavailable)

**Future Building Confidence:** ‚úÖ **READY** - Understand Evo2 integration patterns, multi-modal orchestration, and publication-grade validation workflows.

---

**‚öîÔ∏è DOCTRINE STATUS: ACTIVE - EVO2 PUBLICATION LEARNING COMPLETE** ‚öîÔ∏è

